Eli Lilly's (LLY) Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. COHR

Go back to Eli Lilly's (LLY) Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1164.89 +11.96 (1.04%)
Previous Close $1152.93    52 Week High $88.16 
Open $1144.49    52 Week Low $67.88 
Day High $1170.90    P/E 269.65 
Day Low $1134.41    EPS $4.32 
Volume 2,479,448